Next-generation protein-drug conjugates for cancer therapy
Antibody-drug conjugates (ADCs) represent the fast-growing class of cancer therapeutics. They consist of a highly potent cytotoxic drug linked to an antibody that is specifically targeting certain tumour markers. By combining the cytotoxicity of the drug and the targeting properties of the antibody, ADCs selectively kill cancer cells. The EU-funded TACT project is an innovative, international, multidisciplinary training and research programme designed to train 11 early-stage researchers in the field of anti-cancer therapeutics, creating a new generation of experts. Specifically, the TACT research programme will focus on key principles of the development of a new and more potent generation of protein-drug conjugates employing site-specific bioconjugation methods, environment-specific cleavable linkers, more efficient protein-based targeting systems and new analytical tools for protein characterisation.
Call for proposal
See other projects for this call
Funding SchemeMSCA-ITN-ETN - European Training Networks
WC1E 6BT London
BT63 5QD Craigavon